Octopus Ventures

Not financial or fundraising advice. See full disclaimer.

Tickets

£25K - £100K
£100K - £500K
£500K - £2M
£2M - £10M
£10M - £30M

Rounds

Pre-Seed
Seed
Pre-Series A
Series A
Later Rounds

Sectors

B2B Software
Biotech
Climate / Green
Consumer
Deep Tech
Fintech
Health

Target Geography

United Kingdom
Europe

Last Edited:

October 2, 2025

To suggest a correction to the database, or request to be added or removed from it, contact us at info@adeline.co.uk.

Octopus Ventures has quietly become one of Europe’s most influential venture capital players, backing startups from early ideas through to billion-dollar exits. Founded in 2008 and headquartered in London—with an additional base in New York—Octopus manages approximately £2 billion, investing predominantly in seed and Series A-stage companies, and increasingly at the pre-seed level.

The firm has cultivated a reputation as a long-term partner, distinguished not merely by the size of its chequebook, but by its distinctly people-centric philosophy. Its motto—“venture capital for the founders building a better tomorrow”—is more than marketing fluff. Octopus consistently prioritises investments that promise significant social or environmental impact, making it particularly appealing to founders whose startups are driven by mission as much as profit. Its certified B Corp status further underscores this commitment.

While sector-agnostic in practice, Octopus Ventures leans into specialist expertise across seven distinct areas: B2B software, biotech and healthtech, climate, consumer, deep tech, fintech, and broader healthcare. Notable alumni include household names like Zoopla, Graze, and Depop—the latter of which sold to Etsy in a $1.6 billion deal in 2021.

Founders approaching Octopus can expect a relatively streamlined process, with initial decisions at seed-stage typically made within four weeks. Pre-seed founders, particularly those with compelling visions and strong founding teams, might receive a term sheet within two weeks. However, speed does not diminish thoroughness: Octopus rigorously assesses unit economics, early market traction, and above all, the calibre of the founding team.

Rather than a passive cash injection, founders find themselves supported by a six-person People & Talent team dedicated entirely to helping them scale. Octopus even mandates founder engagement with executive coaching—a rare but positively received requirement designed to build resilience and enhance leadership capacity.

Alex Saint, CEO of Secret Escapes, described Octopus Ventures as genuine partners, saying that its support meant, “we were able to keep the momentum going throughout the funding process. The long-term relationships we have built with the team at Octopus over the last four years has played a crucial role in Secret Escapes’ own development.”

Yet, for all its hands-on involvement, Octopus is known for respecting founder autonomy, preferring supportive collaboration over intrusive interference. Its approachability and humility stand out in a venture landscape often criticised for heavy-handedness.

For UK-based founders with big ideas, particularly those solving meaningful problems, Octopus Ventures offers not only capital but a robust ecosystem designed to nurture both businesses and the people building them.

Pitch Adeline Arts & Science

Adeline is a London-based family office investing in pre-seed, seed and series A startups.

£25K - £100K
£100K - £500K
£500K - £2M
£2M - £10M
£10M - £30M
Pre-Seed
Seed
Pre-Series A
Series A
Later Rounds
B2B Software
Biotech
Climate / Green
Consumer
Deep Tech
Fintech
Health
United Kingdom
Europe

Health AI is no longer a ‘nice to have’: why we are backing founders building a nervous system for healthcare

In 2026, we have entered the era of trillion-dollar biology. Breakthroughs in CRISPR and GLP-1 therapies are reshaping what is possible in human health. Yet the software infrastructure that supports this miracle science and care delivery remains stuck in the late 1990s.

Read More
Arrow pointing right

Is your pre-seed startup solving a real problem? How to validate problem-market fit for VCs in 2025

Why falling in love with an idea can be dangerous; nearly half of failed ventures were solving problems that did not matter enough to enough people.

Read More
Arrow pointing right